Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) is a new dopamine agonist which is capable of producing a sustained response in parkinsonian patients with "on-off" fluctuations when given as a continuous infusion either nasogastrically or intravenously. These data suggest that a sustained release formulation of PHNO may provide a significant, new treatment for patients with "on-off" fluctuations.
Coleman
R J
RJ
Institute of Neurology, Queen Square, London, United Kingdom.
Quinn
N P
NP
Traub
M
M
Marsden
C D
CD
D000328:Adult; D015259:Dopamine Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007441:Intubation, Gastrointestinal / Q000295:instrumentation; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D011597:Psychomotor Performance / Q000187:drug effects
D015259:Dopamine Agents; D010078:Oxazines; C042631:naxagolide; D007980:Levodopa